Article info
PDFResponse
What can the lived experience of participating in risky HIV cure-related studies establish?
- Correspondence to Professor Nir Eyal, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA; neyal{at}hsph.harvard.edu
Citation
What can the lived experience of participating in risky HIV cure-related studies establish?
Publication history
- Received November 16, 2017
- Accepted December 4, 2017
- First published January 10, 2018.
Online issue publication
March 22, 2018
Article Versions
- Previous version (22 March 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
- Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies
- Phase I oncology trials: why the therapeutic misconception will not go away
- Newborn health benefits or financial risk protection? An ethical analysis of a real-life dilemma in a setting without universal health coverage
- How to keep high-risk studies ethical: classifying candidate solutions
- An investigation of patients’ motivations for their participation in genetics-related research
- Vaccine testing for emerging infections: the case for individual randomisation
- A rational cure for prereproductive stress syndrome
- Reconceptualising risk–benefit analyses: the case of HIV cure research
- For love and money: the need to rethink benefits in HIV cure studies